Acute myeloid leukemia expressing the leucocyte integrin CD11b - A new leukaemic syndrome with poor prognosis: Result of an ECOG database analysis

Elisabeth M. Paietta, J. Andersen, J. Yunis, J. M. Rowe, P. A. Cassileth, M. S. Tallman, J. M. Bennett, P. H. Wiernik

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

While assessing the prognostic implications of immunophenotyping in 382 patients enrolled in treatment protocols of the Eastern Cooperative Oncology Group (ECOG) for de novo adult myeloid leukaemia, we identified 95 patients with a unique antigen profile characterized by high expression of the leucocyte integrin CD11b (CD11b+ AML). High expression of CD11b was defined as ≤ 32% positive blasts based on the retrospectively established prognostic cut-off point for this antigen. Although CD11b is normally expressed by mature monocytes, natural killer cells and granulocytes, leukaemic blasts in CD11b+ AML lacked other immunologic monocytic features (e.g. CD14 and CD122, the interleukin-2 receptor β chain) and demonstrated a high degree of immaturity, as reflected by a high incidence of blasts expressing the stem cell factor receptor, CD117, and few blasts positive for the myeloid differentiation antigen CD15. Furthermore, by FAB criteria, only 41% of CD11b+ AML cases were classified as M4/M5. Patients with CD11b+ AML, had a low response rate (54%) when compared with acute monocytic leukaemia (AMOL; 82%, P = 0.006) or AML overall (68%, P = 0.031), independent of age, cytogenetic abnormalities and P-glycoprotein expression. Because of its poor prognosis, recognition of CD11b+ AML is clinically warranted and, given its morphologic and cytogenetic ambiguity, must be based on the unique antigen profile.

Original languageEnglish (US)
Pages (from-to)265-272
Number of pages8
JournalBritish Journal of Haematology
Volume100
Issue number2
DOIs
StatePublished - 1998

Fingerprint

Acute Myeloid Leukemia
Integrins
Leukocytes
Databases
Antigens
Leukemia, Monocytic, Acute
Proto-Oncogene Proteins c-kit
Immunophenotyping
Myeloid Leukemia
Interleukin-2 Receptors
Differentiation Antigens
P-Glycoprotein
Clinical Protocols
Granulocytes
Cytogenetics
Chromosome Aberrations
Natural Killer Cells
Monocytes
Incidence

Keywords

  • Adult
  • AML
  • CD11b
  • New subtype

ASJC Scopus subject areas

  • Hematology

Cite this

Acute myeloid leukemia expressing the leucocyte integrin CD11b - A new leukaemic syndrome with poor prognosis : Result of an ECOG database analysis. / Paietta, Elisabeth M.; Andersen, J.; Yunis, J.; Rowe, J. M.; Cassileth, P. A.; Tallman, M. S.; Bennett, J. M.; Wiernik, P. H.

In: British Journal of Haematology, Vol. 100, No. 2, 1998, p. 265-272.

Research output: Contribution to journalArticle

Paietta, Elisabeth M. ; Andersen, J. ; Yunis, J. ; Rowe, J. M. ; Cassileth, P. A. ; Tallman, M. S. ; Bennett, J. M. ; Wiernik, P. H. / Acute myeloid leukemia expressing the leucocyte integrin CD11b - A new leukaemic syndrome with poor prognosis : Result of an ECOG database analysis. In: British Journal of Haematology. 1998 ; Vol. 100, No. 2. pp. 265-272.
@article{75b7b532fc6849368d2234d97fdf6efc,
title = "Acute myeloid leukemia expressing the leucocyte integrin CD11b - A new leukaemic syndrome with poor prognosis: Result of an ECOG database analysis",
abstract = "While assessing the prognostic implications of immunophenotyping in 382 patients enrolled in treatment protocols of the Eastern Cooperative Oncology Group (ECOG) for de novo adult myeloid leukaemia, we identified 95 patients with a unique antigen profile characterized by high expression of the leucocyte integrin CD11b (CD11b+ AML). High expression of CD11b was defined as ≤ 32{\%} positive blasts based on the retrospectively established prognostic cut-off point for this antigen. Although CD11b is normally expressed by mature monocytes, natural killer cells and granulocytes, leukaemic blasts in CD11b+ AML lacked other immunologic monocytic features (e.g. CD14 and CD122, the interleukin-2 receptor β chain) and demonstrated a high degree of immaturity, as reflected by a high incidence of blasts expressing the stem cell factor receptor, CD117, and few blasts positive for the myeloid differentiation antigen CD15. Furthermore, by FAB criteria, only 41{\%} of CD11b+ AML cases were classified as M4/M5. Patients with CD11b+ AML, had a low response rate (54{\%}) when compared with acute monocytic leukaemia (AMOL; 82{\%}, P = 0.006) or AML overall (68{\%}, P = 0.031), independent of age, cytogenetic abnormalities and P-glycoprotein expression. Because of its poor prognosis, recognition of CD11b+ AML is clinically warranted and, given its morphologic and cytogenetic ambiguity, must be based on the unique antigen profile.",
keywords = "Adult, AML, CD11b, New subtype",
author = "Paietta, {Elisabeth M.} and J. Andersen and J. Yunis and Rowe, {J. M.} and Cassileth, {P. A.} and Tallman, {M. S.} and Bennett, {J. M.} and Wiernik, {P. H.}",
year = "1998",
doi = "10.1046/j.1365-2141.1998.00561.x",
language = "English (US)",
volume = "100",
pages = "265--272",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Acute myeloid leukemia expressing the leucocyte integrin CD11b - A new leukaemic syndrome with poor prognosis

T2 - Result of an ECOG database analysis

AU - Paietta, Elisabeth M.

AU - Andersen, J.

AU - Yunis, J.

AU - Rowe, J. M.

AU - Cassileth, P. A.

AU - Tallman, M. S.

AU - Bennett, J. M.

AU - Wiernik, P. H.

PY - 1998

Y1 - 1998

N2 - While assessing the prognostic implications of immunophenotyping in 382 patients enrolled in treatment protocols of the Eastern Cooperative Oncology Group (ECOG) for de novo adult myeloid leukaemia, we identified 95 patients with a unique antigen profile characterized by high expression of the leucocyte integrin CD11b (CD11b+ AML). High expression of CD11b was defined as ≤ 32% positive blasts based on the retrospectively established prognostic cut-off point for this antigen. Although CD11b is normally expressed by mature monocytes, natural killer cells and granulocytes, leukaemic blasts in CD11b+ AML lacked other immunologic monocytic features (e.g. CD14 and CD122, the interleukin-2 receptor β chain) and demonstrated a high degree of immaturity, as reflected by a high incidence of blasts expressing the stem cell factor receptor, CD117, and few blasts positive for the myeloid differentiation antigen CD15. Furthermore, by FAB criteria, only 41% of CD11b+ AML cases were classified as M4/M5. Patients with CD11b+ AML, had a low response rate (54%) when compared with acute monocytic leukaemia (AMOL; 82%, P = 0.006) or AML overall (68%, P = 0.031), independent of age, cytogenetic abnormalities and P-glycoprotein expression. Because of its poor prognosis, recognition of CD11b+ AML is clinically warranted and, given its morphologic and cytogenetic ambiguity, must be based on the unique antigen profile.

AB - While assessing the prognostic implications of immunophenotyping in 382 patients enrolled in treatment protocols of the Eastern Cooperative Oncology Group (ECOG) for de novo adult myeloid leukaemia, we identified 95 patients with a unique antigen profile characterized by high expression of the leucocyte integrin CD11b (CD11b+ AML). High expression of CD11b was defined as ≤ 32% positive blasts based on the retrospectively established prognostic cut-off point for this antigen. Although CD11b is normally expressed by mature monocytes, natural killer cells and granulocytes, leukaemic blasts in CD11b+ AML lacked other immunologic monocytic features (e.g. CD14 and CD122, the interleukin-2 receptor β chain) and demonstrated a high degree of immaturity, as reflected by a high incidence of blasts expressing the stem cell factor receptor, CD117, and few blasts positive for the myeloid differentiation antigen CD15. Furthermore, by FAB criteria, only 41% of CD11b+ AML cases were classified as M4/M5. Patients with CD11b+ AML, had a low response rate (54%) when compared with acute monocytic leukaemia (AMOL; 82%, P = 0.006) or AML overall (68%, P = 0.031), independent of age, cytogenetic abnormalities and P-glycoprotein expression. Because of its poor prognosis, recognition of CD11b+ AML is clinically warranted and, given its morphologic and cytogenetic ambiguity, must be based on the unique antigen profile.

KW - Adult

KW - AML

KW - CD11b

KW - New subtype

UR - http://www.scopus.com/inward/record.url?scp=0031990847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031990847&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1998.00561.x

DO - 10.1046/j.1365-2141.1998.00561.x

M3 - Article

C2 - 9488612

AN - SCOPUS:0031990847

VL - 100

SP - 265

EP - 272

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -